Evidence and Supporting Information
SweetBio APIS® + VERIS™ have been found to be an effective treatment for a variety of chronic and acute wounds such as non-healing diabetic foot ulcers and Mohs skin cancer surgical sites. Multiple clinical evaluations support the ability to close wounds in 4 – 8 weeks while in vitro data demonstrates reduced bacterial load, decreased MMP-9, and triggering the release of growth factors. See peer-reviewed journal publications below for more details on the performance and impact that APIS® + VERIS™ has on wounds.
Clinical Publications
37 Patient Mohs Dermatologic Surgery RCT
Published in Dermatologic Surgery, this randomized controlled trial (RCT) conducted by the Dermatology Department at Vanderbilt University Medical Center compared SweetBio®’s technology and secondary intention healing (SIH) to support wound closure post-Mohs. Results demonstrated improved wound healing with SweetBio®’s technology showing significant reduction in pain scores and favorable skin thickness.
12 Patient Lower Extremity Chronic Wound Case Series
Published in The International Journal of Lower Extremity Wounds, this clinical evaluation involved 5 physicians across 4 states using SweetBio®’s technology to treat non-healing chronic ulcers. Patients achieved 100% closure within 8 weeks, with a mean closure time of 4.1 weeks.
8 Patient Mohs Dermatologic Surgery Case Series
Published in Dermatologic Surgery, this clinical evaluation conducted by the Dermatology Department at Vanderbilt University Medical Center used SweetBio®’s technology to support wound closure post Mohs (skin cancer removal) surgery. Results demonstrated complete re-epithelialization was achieved within an average of 6 weeks.
43 Patient Chronic Wound Healing in an Urban Hospital Wound Clinic
Published in Wounds, this retrospective IRB-approved clinical evaluation assessed chronic wound closure rates using standard of care (SOC) or treatment with SweetBio®’s technology in an urban hospital wound clinic. In both groups, most wounds did not close for several reasons, mainly patient compliance. For wounds that did close, the average time to closure was two times faster for SweetBio®’s technology compared to SOC (7.4 weeks and 14.8 weeks, respectively; p < .05).
In Vitro Publications
Bacteria Reduction
Published in Biomedical & Translational Science, this data demonstrates SweetBio®’s technology ability to significantly reduce both Staphylococcus Aureus and Pseudomonas Aeruginosa by 99.99% compared to a non-treated surface after 24 hours, in vitro.
Controlling Inflammation and Growth Factors
Published in the International Journal of Biomaterials, this data demonstrates SweetBio®’s technology ability to significantly decrease (to negligible levels) the expression of MMP-9 from macrophages and trigger the release of pro-regenerative growth factors from fibroblasts such as FGFb and VEGF, in vitro.
Direct Comparison of Collagen Dressing vs. Manuka Honey Dressing vs. SweetBio®’s Technology
Published in the International Journal of Molecular Sciences, this data highlights the superior comprehensive approach that SweetBio®’s technology has over collagen dressings and Manuka honey dressings, specifically comparing MMP-9/TIMP-1 ratios and pro-regenerative growth factor secretion, in vitro.